5 Stocks Pulling The Health Services Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 119 points (0.7%) at 16,493 as of Wednesday, Jan. 15, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,941 issues advancing vs. 990 declining with 158 unchanged.

The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include HCA Holdings ( HCA), down 1.0%, Grifols ( GRFS), down 1.0% and Smith & Nephew ( SNN), down 0.7%. Top gainers within the industry include Globus Medical ( GMED), up 4.6%, Edwards Life ( EW), up 3.4% and Express Scripts ( ESRX), up 0.8%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry lower today. As of noon trading, WuXi PharmaTech (Cayman is down $1.21 (-3.2%) to $36.83 on average volume. Thus far, 250,468 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 626,100 shares. The stock has ranged in price between $36.75-$38.38 after having opened the day at $38.38 as compared to the previous trading day's close of $38.04.

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.7 billion and is part of the health care sector. The company has a P/E ratio of 25.6, above the S&P 500 P/E ratio of 17.7. Shares are down 1.0% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full WuXi PharmaTech (Cayman Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Opko Health ( OPK) is down $0.18 (-2.0%) to $8.82 on average volume. Thus far, 2.2 million shares of Opko Health exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $8.73-$9.15 after having opened the day at $9.03 as compared to the previous trading day's close of $9.00.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $3.6 billion and is part of the health care sector. Shares are up 6.6% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, DaVita HealthCare Partners ( DVA) is down $0.37 (-0.6%) to $64.60 on light volume. Thus far, 395,108 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $64.52-$65.00 after having opened the day at $65.00 as compared to the previous trading day's close of $64.97.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $13.7 billion and is part of the health care sector. The company has a P/E ratio of 24.2, above the S&P 500 P/E ratio of 17.7. Shares are up 2.5% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Intuitive Surgical ( ISRG) is down $11.85 (-2.8%) to $408.03 on heavy volume. Thus far, 448,499 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 439,700 shares. The stock has ranged in price between $402.18-$421.08 after having opened the day at $420.56 as compared to the previous trading day's close of $419.88.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $15.0 billion and is part of the health care sector. The company has a P/E ratio of 23.5, above the S&P 500 P/E ratio of 17.7. Shares are up 9.3% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Intuitive Surgical a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full Intuitive Surgical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, WellPoint ( WLP) is down $0.65 (-0.7%) to $90.70 on average volume. Thus far, 957,754 shares of WellPoint exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $90.59-$91.90 after having opened the day at $91.71 as compared to the previous trading day's close of $91.35.

WellPoint, Inc., a health benefits company, through its subsidiaries, offers network-based managed care plans to large and small employer, individual, Medicaid, and senior markets in the United States. The company operates through three segments: Commercial, Consumer, and Other. WellPoint has a market cap of $26.8 billion and is part of the health care sector. The company has a P/E ratio of 9.8, below the S&P 500 P/E ratio of 17.7. Shares are down 1.1% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate WellPoint a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full WellPoint Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call